About the Company
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARPO News
Aerpio Pharmaceuticals' Razuprotafib Dropped From Collaborative COVID-19 Trial
Quantum Leap Healthcare Collaborative-sponsored I-SPY COVID Trial will not further test Aerpio Pharmaceuticals Inc's (NASDAQ: ARPO) razuprotafib. Razuprotafib was chosen because it was believed to ...
Kevin G. Peters's Net Worth
Who is Kevin G. Peters? Kevin G. Peters does not have any significant net worth to report based on the numbers we have. This is based on reported shares in Aerpio Pharmaceuticals, Inc..
TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)
Aadi Bioscience (AADI) Company Description: Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product ...
Stephen J Hoffman's Net Worth
Who is Stephen J Hoffman? Stephen J Hoffman does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
MRNS Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure ...
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton ...
ARDS Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.
Merrimack Pharmaceuticals Inc MACK
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Rhythm Pharmaceuticals Inc RYTM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.33. MIRM isn't one of the 30 most popular stocks among hedge funds at the end of the ...
Q4 2023 Cumberland Pharmaceuticals Inc Earnings Call
Todd Anthony; VP & Organizational Development; Cumberland Pharmaceuticals Inc. Operator Good afternoon, and welcome to Cumberland Pharmaceuticals 2023 financial report and company. Our call is ...
Loading the latest forecasts...